



IFW/J

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CALVANI et al

Atty. Ref.: 4865-78; Confirmation No. 8374

Appl. No. 10/537,057

TC/A.U. 1614

Filed: June 2, 2005

Examiner:

For: USE OF PROPIONYL L-CARNITINE FOR THE PREPARATION OF A MEDICAMENT
FOR THE TREATMENT OF GLAUCOMA

* * * * *

May 23, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PETITION TO CORRECT INVENTORSHIP IN A PATENT APPLICATION
UNDER 37 CFR §1.48(a)(1)

I am advised by my client that Nicola Pescosolido was inadvertently omitted as being named as one of the inventors of the above-identified application. My client has directed me to seek correction of this oversight by including Nicola Pescosolido as one of the inventors and submitted with this Petition is a Statement from the person being added as an inventor that the error in inventorship occurred without deceptive intention on this person's part.

The application is assigned and submitted herewith is a Consent of the Assignee to add Nicola Pescosolido as an inventor.

The processing fee under 37 CFR §1.17(I) is submitted with this Petition.

The Commissioner is hereby authorized to charge our Deposit Account No. 14-1140 for any fees required in connection with the filing of this paper.

05/24/2007 YPOLITE1 00000004 10537057


01 FC:1464

130.00 0P

CALVANI et al
Appl. No. 10/537,057
May 23, 2007

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Arthur R. Crawford
Reg. No. 25,327

ARC:eaw
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CALVANI et al Atty. Ref.: 4865-78; Confirmation No. 8374

Appl. No. 10/537,057 TC/A.U. 1614

Filed: June 2, 2005 Examiner:

For: USE OF PROPIONYL L-CARNITINE FOR THE PREPARATION OF A MEDICAMENT
FOR THE TREATMENT OF GLAUCOMA

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST TO CORRECT INVENTORSHIP UNDER 37 CFR §1.48(a)(2)

I, Nicola Pescosolido, a citizen of Italy, residing at Via Paolo Albera, 33, I-00181 Roma, Italy, am familiar with the contents of U.S. application Serial No. 10/537,057 and have read and understood this application including the claims.

2. That I was not named in the original application papers and omitted as an inventor and that this error arose without any deceptive intention on my part.
3. That I regard myself as being a joint inventor together with Menotti Calvani and Emilia Reda and that I request to be included as one of the inventors in respect of the above-identified application.
4. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Nicola Pescosolido

Date: 27/4/07



RULE 63 (37 C.F.R. 1.63)
INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

USE OF PROPIONYL L-CARNITINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF GLAUCOMA

the specification of which (check applicable box(es)):

- is attached hereto
 was filed on June 2, 2005 as U.S. Application Serial No. 10/537,057 (Alt. Dkt. No. 4865-78)
 was filed as PCT International application No. PCT/IT2003/000566 on 23 September 2003

and (if applicable to U.S. or PCT application) was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
RM2002A000492	Italy	1 October 2002

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.



Application Number	Day/Month/Year Filed
--------------------	----------------------

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below:

Prior U.S./PCT Application(s): Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
PCT/IT2003/000566	23 September 2003	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint Nixon & Vanderhye P.C., telephone number 703-816-4000 (to whom all communications are to be directed) and the attorneys of: **Customer Number 23117**, individually and collectively

owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent. I also authorize Nixon & Vanderhye to add or delete attorneys from that Customer Number, and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1.	Inventor's Signature:			Date: <u>13/04/07</u>
	Inventor:	Menotti (first)	MI	Italian (citizenship)
	Residence: (city)	Roma	(state/country)	Italy
	Mailing Address:	c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, km 30, 400 Pomezia, Roma, Italy		
	(Zip Code)	I-00040		
2.	Inventor's Signature:			Date: <u>13.04.2007</u>
	Inventor:	Emilia (first)	MI	Italian (citizenship)
	Residence: (city)	Roma	(state/country)	Italy
	Mailing Address:	c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, km 30, 400 Pomezia, Roma, Italy		
	(Zip Code)	I-00040		

See attached sheet(s) for additional inventor(s) information!!

4865-78

Serial No. 10/537,057

Page 2

Nixon & Vanderhye P.C. (10/99)
(Domestic Non-Assigned/Foreign)

3. Inventor's Signature:

Inventor:

Nicola Gerosa

Date:

27/4/07

Italian
(citizenship)

Residence: (city)

Roma

MI

PESCATORE
(last)

Italy

Mailing Address:

Via Paolo Albera, 33, Roma, Italy

I-00181

(state/country)

1190438



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CALVANI et al Atty. Ref.: 4865-78; Confirmation No. 8374

Appl. No. 10/537,057 TC/A.U. 1614

Filed: June 2, 2005 Examiner:

For: USE OF PROPIONYL L-CARNITINE FOR THE PREPARATION OF A MEDICAMENT
FOR THE TREATMENT OF GLAUCOMA

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

CONSENT OF ASSIGNEE TO CORRECT INVENTORSHIP UNDER 37 CFR §1.48(a)(5)

Giulia TAGLIAFICO

That I, _____, acting in my representative capacity hereby
state as follows:

1. That I am an authorized representative of Sigma-Tau Industrie Farmaceutiche Riunite
S.p.A., the assignee of the above-identified application by virtue of an Assignment recorded on
June 2, 2005 at Reel 017397, Frame 0379.

2. That on behalf of the assignee consent is given to include

Nicola PESCO SOLLIO as an inventor in respect of this application.

SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

SIGMA TAU
IND. FARM. RIUNITE S.p.A.
Viale Shakespeare, 47
00144 ROMA

By _____

Name: _____
Title: _____

Giulia TAGLIAFICO

Head of Corporate Patent Dept.

Date: 02/May/2007